Related Experiment Videos
Alprazolam dependence prevented by substituting with the beta-carboline abecarnil
G Pinna1, R Galici, H H Schneider
1Research Laboratories of Schering AG, Berlin, Germany.
Summary
Abruptly stopping benzodiazepines (BDZs) causes severe withdrawal. Replacing BDZs with abecarnil in mice effectively prevented these benzodiazepine withdrawal symptoms, offering a new tapering method.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Medicine
Background:
- Abrupt cessation of benzodiazepines (BDZs) in humans causes discontinuation syndrome, including anxiety and seizures.
- Gradual dose reduction (tapering) often still results in dependence signs.
- Novel methods are needed to wean patients from BDZs safely.
Purpose of the Study:
- To investigate novel strategies for mitigating benzodiazepine (BDZ) discontinuation syndrome.
- To evaluate the efficacy of beta-carbolines in preventing BDZ withdrawal symptoms.
Main Methods:
- Mice underwent chronic alprazolam treatment, followed by abrupt termination.
- Alprazolam was replaced with the beta-carboline abecarnil or the antagonist ZK93426.
- Withdrawal symptoms, including anxiety, muscle rigidity, and seizures, were monitored.
Main Results:
- Mice exhibited significant signs of benzodiazepine withdrawal syndrome for 28 days after alprazolam cessation.
- Replacement therapy with abecarnil for 7 days successfully prevented withdrawal symptoms.
- Substitution with the beta-carboline antagonist ZK93426 exacerbated the discontinuation syndrome.
Conclusions:
- Abecarnil shows promise as a replacement therapy to facilitate rapid tapering of benzodiazepines (BDZs).
- This beta-carboline strategy may offer a novel approach to managing benzodiazepine (BDZ) dependence and withdrawal.